Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon
Start of recruitment of 12 patients planned during the 4th quarter of 2023 in 4 French centers
First results of the study expected in mid-2024
Lyon (France) and Cambridge (MA, US), October 24, 2023 – 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments against resistant bacterial infections, announces that it has received approval from the National Agency for the Safety of Medicines and Health Products (ANSM) and the Committee for the Protection of People (CPP) Sud-Est II-Lyon of the protocol of its phase 1 study in infectious endocarditis caused by Staphylococcus aureus (S. aureus).
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]
Source link -86